Differences in recommendations between the Allergic Rhinitis and its Impact on Asthma Update 2010 and US Rhinitis Practice Parameters

Journal of Allergy and Clinical Immunology

Volumn 127, Issue 6, 2011, Pages

  Chipps, Bradley ^a   Spector, Sheldon ^b   Farrar, Judith ^c   Carr, Warner ^d   Meltzer, Eli ^e   Storms, William ^f   Kaliner, Michael ^g   Luskin, Allan ^h   Bukstein, Donald ⁱ   Oppenheimer, John ^j   Smart, Brian ^k   Derebery, Jenifer ^l   Harder, Julia ^a   Dykewicz, Mark ^m   Benninger, Michael ⁿ  

^a Capital Allergy and Respiratory Disease Center   (United States)

^b California Allergy and Asthma Medical Group   (United States)

^c Life Sciences Press   (United States)

^d Allergy & Asthma Associates of Southern California   (United States)

^e ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^f William Storms Allergy Clinic   (United States)

^g Institute for Asthma and Allergy   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ Dean Clinic   (United States)

^j Pulmonary and Allergy Associates PA   (United States)

^k DuPage Medical Group Eye Specialists   (United States)

^l HOUSE EAR INSTITUTE   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁿ LERNER RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OLOPATADINE;

ALLERGIC RHINITIS; ASTHMA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAY FEVER; HUMAN; LETTER; NOSE CONGESTION; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; SUBLINGUAL IMMUNOTHERAPY; UNSPECIFIED SIDE EFFECT;

EID: 79957809135     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2011.01.070     Document Type: Letter

References (9)

1. E1. Berger W, Hampel F Jr, Bernstein J, Shah S, Sacks H, Meltzer EO. Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2006;97:375-81. (Pubitemid 44476575)
2. E2. Corren J, Storms W, Bernstein J, Berger W, Nayak A, Sacks H, et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 2005;27:543-53. (Pubitemid 40835965)
3. Kaliner MA, StormsW, Tilles S, Spector S, Tan R, LaForce C, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 mcg in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 2009;30:255-62.
4. Kalpaklioglu AF, Kavut AB. Comparison of azelastine versus triamcinolone nasal spray in allergic and nonallergic rhinitis. Am J Rhinol 2010;24:29-33.
5. Kaliner MA, Oppenheimer J, Farrar JR. Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc 2010;31:112-9.
6. Ratner PH, Hampel F, van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:74-81.
7. Hampel FC, Ratner PH, Van Bavel J, Amar NJ, Daftary P, Wheeler W, Sacks H. Double-blind, placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device. Ann Allergy Asthma Immunol 2010;105: 168-73.
8. LaForce CF, Carr W, Tilles SA, Chipps BE, Storms W, Meltzer EO, Edwards M. Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis. Allergy Asthma Proc 2010;31:132-40.
9. Bachert C, Bousquet J, Canonica GW, Durham SR, Klimek L, Mullol J, et al. Levocetirizine improves quality of life and reduces cost in long-term managementof persistent allergic rhinitis. J Allergy Clin Immunol 2004;114:838-44.